ISSN: 2578-3335 (Print) 2578-3343 (Online)
Volume 3

Issue 1

Article 6

2021

IgM Multiple Myeloma: A Rare Clinical Entity and Diagnostic
Dilemma
Keerthy Joseph
Mercy Catholic Medical Center, keerthyjo@pcom.edu

Alison Greidinger
Cooper University Hospital, greidinger-alison@cooperhealth.edu

Marjan Koch
Cooper University Hospital, koch-marjan@cooperhealth.edu

Eric Behling
Cooper University Hospital, behling-eric@cooperhealth.edu

Tulin Budak-Alpdogan
Cooper University Hospital, budak-alpdogan-tulin@cooperhealth.edu

Cooper Rowan Medical Journal: https://rdw.rowan.edu/crjcsm
Would you like to be a reviewer? Please fill in this short form to express your interest.
Recommended Citation
Joseph, Keerthy; Greidinger, Alison; Koch, Marjan; Behling, Eric; and Budak-Alpdogan, Tulin (2022) "IgM
Multiple Myeloma: A Rare Clinical Entity and Diagnostic Dilemma," Cooper Rowan Medical Journal: Vol. 3:
Iss. 1, Article 6.
DOI: 10.31986issn.2578.3343_vol3iss1.5
Available at: https://rdw.rowan.edu/crjcsm/vol3/iss1/6

This work is licensed under a Creative Commons Attribution 4.0 License.
This Case Reports and Case Series is brought to you for free and open access by the Rowan University Journals at
Rowan Digital Works. It has been accepted for inclusion in Cooper Rowan Medical Journal by an authorized editor
of Rowan Digital Works. For more information, please contact brush@rowan.edu.

IgM Multiple Myeloma: A Rare Clinical Entity and Diagnostic Dilemma

This case reports and case series is available in Cooper Rowan Medical Journal: https://rdw.rowan.edu/crjcsm/vol3/
iss1/6

Joseph et al.: A Case Report of IgM Multiple Myeloma

IgM Multiple Myeloma: A Rare Clinical Entity and
Diagnostic Dilemma
Keerthy Joseph, DO1∗, Alison Greidinger, MD2, Marjan Koch, MD2, Eric Behling,
MD2 & Tulin Budak-Alpdogan, MD2
1

Mercy Catholic Medical Center, Philadelphia, PA
2

Cooper University Hospital, Camden, NJ

*Corresponding author: keerthyjo@pcom.edu (Keerthy Joseph, DO)

ABSTRACT
IgM multiple myeloma is a rare disease that shares many common features with Waldenström
macroglobulinemia and lymphoplasmacytic lymphoma. It has been described in the literature as having
unique diagnostic findings that separate it from the more common IgG and IgA myelomas. It is important
for physicians to be able to differentiate between IgM multiple myeloma, Waldenström
macroglobulinemia and lymphoplasmacytic lymphoma as their treatments vastly differ. This case report
describes the clinical presentation of a patient with IgM lambda multiple myeloma and highlights the
pathologic and clinical findings that are specific to this rare entity. We aim to provide further evidence for
the previously reported diagnostic criteria for IgM multiple myeloma.
Keywords: IgM Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic lymphoma,
Fluorescent In Situ Hybridization, Molecular testing

INTRODUCTION:

Multiple myeloma (MM) is a hematologic malignancy characterized as a plasma cell dyscrasia marked by
elevation of monoclonal immunoglobulins.1 IgM MM is an extremely rare entity representing less than
0.5% of all myeloma diagnoses.2 Distinguishing between IgM MM and Waldenström macroglobulinemia
(WM) – a condition marked by a clonal lymphoplasmacytic population in the bone marrow and a
monoclonal IgM gammopathy in the peripheral blood – can be challenging. Distinguishing these entities
has clinical importance, as the treatments are different. The International Myeloma Working Group
(IMWG) criterion is used to diagnose the more common IgG and IgA myelomas,3 however, this distinct
entity is suggested to have unique diagnostic criteria by Schuster et al.4
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They describe IgM MM as a symptomatic clonal plasma cell proliferative disorder, regardless of IgM
monoclonal protein size, with 10% or more plasma cells in the bone marrow, lytic bone lesions and a
t(11;14) translocation. Some groups have proposed also using molecular testing to assist with diagnosis of
IgM MM including CXCR4 and MYD88 negativity.4–7 Here, we present the case of a patient diagnosed
with the extremely rare entity of IgM multiple myeloma, while highlighting several key features that are
utilized to distinguish IgM MM from WM.
Case:
An 88 year old male with history of smoldering myeloma, and neuropathy presented with complaints of
midsternal chest pain and back pain for 2 months. He was first diagnosed with smoldering myeloma in
2012, when SPEP showed an M-spike of 0.2 g/dL with immunofixation revealing an IgM lambda
monoclonal gammopathy. Free kappa/lambda ratio was 0.14. Bone marrow biopsy showed 15% plasma
cells. The patient was diagnosed with smoldering myeloma and followed with active surveillance. His
most recent skeletal survey was 17 months prior to this hospitalization and was negative for lytic lesions.
Labs at that time did not reveal any anemia, hypercalcemia, or renal dysfunction. M-spike was stable at
0.3g/dL with free kappa/lambda ratio of 0.13. With regards to his neuropathy, anti-MAG IgM testing was
performed in 2013 and showed a titer of <1:1600 making it very unlikely that his neuropathy was related
to his IgM paraprotein.
In June 2021, he developed 2 months of midsternal chest and back pain. On presentation to the emergency
room, vital signs were stable. Acute coronary syndrome was ruled out with normal troponins, and EKG
without any ischemic patterns. Labs on admission were notable for mild anemia with hemoglobin of 11.5
g/dL, which was 13.5 g/dL one year prior, and an elevated calcium of 11.5 mg/dL. Renal function was
stable with a creatinine of 0.99 mg/dL. Computed tomography angiography chest was negative for acute
pulmonary embolism; however, it did show diffuse osteopenia with multiple lytic lesions throughout the
osseous structures of the chest, abdomen, and pelvis, which were suspicious for multiple myeloma (MM).
Additionally, there were acute/subacute appearing manubrial and sternal pathologic fractures. CT brain
revealed patchy lucent lesions in the calvarium and skull base, consistent with MM. CT abdomen was
negative for any organomegaly or lymphadenopathy. His SPEP revealed an M-spike of 1.7g/dL with
immunofixation showing an IgM lambda monoclonal band, consistent with his prior smoldering myeloma
phenotype (Figure 1 ). Free kappa/lambda ratio was 0.03.
Immunoglobulin panel showed an elevated IgM level of 3,060 mg/dL and decreased levels of IgA and IgG,
<5mg/dL and 367 mg/dL, respectively. He had elevated beta-2 microglobulin, 5.69 mg/L, and low
albumin, 2.9g/dL. Lactate dehydrogenase (LDH) was 282 U/L. To confirm the diagnosis of multiple
myeloma and formally rule out WM, a bone marrow biopsy was performed revealing a hypercellular bone
https://rdw.rowan.edu/crjcsm/vol3/iss1/6
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Figure 1 (A) Serum protein electrophoresisdemonstrates a prominent M-spike [1] in the gamma region which is
quantitatedat 1.7 g/dL. (B) Immunofixationcharacterizes the M-spike as IgM lambda.

marrow with 70-80% plasmacytosis (Figure 2). Importantly, immunohistochemical staining for
B-lymphocytes was negative. Congo red staining was negative for amyloid. MM fluorescence in situ
hybridization (FISH) panel was positive for t(11;14) and trisomy 15, and with these findings he had a
hyper-diploid MM. Chemokine receptor type 4 (CXCR4) and MYD88 mutations were not detected.
In light of his overall deconditioned state, poor prognosis, and in efforts to preserve his quality of life at
the age of 88, goals of care discussion was initiated with the patient and family. Ultimately, the decision
was made to attempt myeloma directed therapy inpatient and he received 5 days of steroids and 1 day of
bortezomib. His clinical condition continued to deteriorate and per family wishes in discussion with the
hematology team, he was transitioned to inpatient hospice. The patient passed away on day 12 of
hospitalization.
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Figure 2 Bone marrow involvedby multiple myeloma: (A) Bone marrow core biopsy showing complete effacement
bysheets of plasma cells (H&E x400). (B, inset) Bone marrow aspirate smearwith marked plasmacytosis (Wright
Giemsa x1000). (C-E) The neoplastic plasmacells are diffusely positive for CD138 and show lambda light chain
restrictionby immunohistochemistry (x400).

DISCUSSION & CONCLUSION:

IgM MM is an extremely rare entity and comprises less than 0.5% of all reported MM cases.2 It has been
characterized as a clonal plasma cell infiltration of the bone marrow of 10% or greater plus lytic bone
lesions and a t(11;14) translocation.4 WM, by contrast, is characterized by a clonal lymphoplasmacytic
infiltration of the bone marrow of any quantity as well as a monoclonal IgM paraprotein in the peripheral
blood.6 Given that IgM monoclonal gammopathy is a common feature of both IgM MM and WM,
distinguishing between the two entities is often challenging. Whereas mostMost cases of MM have
anemia, renal insufficiency, and lytic osseous lesions as the major features, in contrast, WM is often
characterized by hyperviscosity, lymphadenopathy, organomegaly, and peripheral neuropathy.2 From a
https://rdw.rowan.edu/crjcsm/vol3/iss1/6
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pathological perspective, bone marrow biopsies in WM will show an infiltration of clonal
lymphoplasmacytic cells, whereas pure plasmacytic morphology is seen in IgM MM (Table 1 ).8 Although
not pathognomonic for WM, the MYD88 gene, which is a myeloid differentiation primary response gene,
is mutated in 80-95% of WM cases and is highly characteristic of WM.5–7 The absence of an MYD88
mutation does not rule out WM, however, this mutation has not been reported in any IgM MM cases.5,6 It
is also important to note that 20-40% of WM patients have activating mutations in the C-terminal domain
of the C-X-C chemokine receptor type 4 (CXCR4) gene.6 Initial testing for both MYD88 and CXCR4
gene mutations has been suggested as a potential tool to assess tumor burden in WM patients.9 Another
helpful marker to help aid in the diagnosis of IgM MM is Cyclin D1 expression and detection of
translocation t(11;14), which usually favors a diagnosis of MM over WM.6
In our patient, the lytic lesions, hypercalcemia, and anemia present on admission was pathognomonic for
MM, however given the rarity of IgM MM, extensive testing on bone marrow biopsy was performed. Bone
marrow biopsy revealed a total absence of B-lymphocytes, both by flow cytometry and
immunohistochemical staining. This was highly suggestive of MM however it is important to note that
CD20 positivity is seen in IgM MM and is not a reliable marker.10 The expression of CD56 by plasma
cells essentially eliminated lymphoplasmacytic lymphoma and other B-cell lymphomas from the
differential diagnosis. In a study involving 55 MM patients, it was concluded that strong CD56 expression
is common in MM and that CD56 expression is near absent in polyclonal plasma cells from non-neoplastic
tissue sites.11 Additionally, t(11,14) seen on FISH analysis and absence of MYD88 and CXCR4 mutations
supported the diagnosis of MM.
Table 1 Clinical,laboratory and pathologic findings of IgM MM vs WM

IgM Multiple Myeloma

Waldenström Macroglobinemia

Clinical Findings Bone pain and lytic lesions

Clinical Findings Organomegaly

Neuropathy

Lymphadenopathy Neuropathy

Laboratory Findings Hyperviscosity Serum IgM clonal

Laboratory Findings Hyperviscosity Serum

paraprotein Abnormal K/L ratio Anemia

IgM clonal paraprotein

Hypercalcemia Elevated creatinine
Common IHC, FISH and Molecular Findings Bone

Common IHC, FISH and Molecular Findings

marrow >10% plasma cells CD5- CD20+/- CD56+

CD20+ 6q deletion (55%)12 MYD88 mutation

CD117+/- CD138+ t(11;14)

CXCR4 mutation
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Despite the similarities between MM and WM, it is crucial for clinicians to have the tools to differentiate
between the two diagnoses as their management is different. MM is typically managed with induction
therapy consisting of triple or even quadruple therapy with steroids, proteasome inhibitors,
immunomodulators and monoclonal antibodies, followed by hematopoietic stem cell (HSC) transplant
depending on cytogenetic findings, minimal residual disease, and transplant eligibility. Following
transplant, there is a subsequent maintenance therapy phase.12 In contrast, WM management is driven by
symptom severity, in which emergent plasmapheresis is utilized for symptoms of hyperviscosity, usually
when serum IgM levels >4000 mg/dL, in addition to therapy aimed at the malignant clone. Rituximab
based therapies or BTK inhibitors are utilized in the first line setting, further highlighting the difference
between WM and MM, given the presence of CD20+ B-lymphocytes seen in WM.13
Unfortunately, our patient presented with severe sternal and rib fractures leading to significant atelectasis
and eventual respiratory failure. Despite initiation of treatment with bortezomib and steroids, his clinical
condition deteriorated. Interestingly, following initiation of MM directed therapy, his IgM level dropped
from 3,060mg/dL to 1,620mg/dL, however, he was too clinically unstable to pursue further therapy.
This paper provides a discussion of a case of IgM MM, a rare clinical entity. It explores the key features of
the diagnostic workup for MM, in addition to highlighting the unique clinical and pathologic features that
can help physicians distinguish IgM MM from WM.
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